查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612571

生物標記市場：按產品/服務、類型、疾病和應用分類 - 全球預測 2025-2030

Biomarkers Market by Product & Service (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生物標記市場價值為525億美元，預計到2024年將達到596.9億美元，複合年成長率為14.19%，到2030年將達到1329.8億美元。

生物標記（生物標記）是一種在體液和組織中發現的特徵性生物特徵，顯示正常或異常狀況、疾病階段或治療效果。它對於診斷、臨床試驗、個人化醫療和藥物開發至關重要，並加深我們對疾病機制和治療效果的理解。生物標記用於腫瘤學、心臟病學、神經病學和感染疾病等領域。慢性病的增加、生物標記研究的技術進步以及精準醫療需求的快速成長推動了市場成長。基因生物標記的創新，特別是透過人工智慧和資料分析的進步，為客製化個人化治療計畫和預測疾病進展提供了重要機會。液態切片和多組體學物標記等新領域正在引起人們的關注，因為它們有可能更快、更準確地檢測疾病。然而，挑戰包括檢驗成本高、監管複雜性以及有關基因資料隱私的道德問題。此外，疾病異質性和生物標記檢驗缺乏標準化正在阻礙市場擴張成長。透過探索非侵入性生物標記和人工智慧增強的分析工具，可以實現持續創新。整合數位健康資料和現實世界的證據可以帶來更具預測性的診斷。透過投資跨產業合作，公司可以透過確保採用穩健的多學科方法來發現生物標記，從而獲得競爭優勢。鼓勵開放資料共用和標準化通訊協定可以改善一些現有障礙。隨著生物標記物市場的發展，靈活應對監管變化和技術進步將是持續成長的關鍵。透過強調與醫療保健提供者和患者的夥伴關係，生物標記的應用將變得更加創新，從而顯著改善健康結果和個人化醫療保健解決方案的市場滲透率。

主要市場統計
基準年[2023] 525億美元
預測年份 [2024] 596.9億美元
預測年份 [2030] 1329.8億美元
複合年成長率（%） 14.19%

市場動態：揭示快速發展的生物標記市場的關鍵市場洞察

供需的動態交互作用正在改變生物標記市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 擴大使用生物標記來早期檢測和診斷慢性病
    • 政府和監管機構對生物標記研究的支持
    • 擴大生物標記在個人化醫療中的使用
  • 市場限制因素
    • 與生物標記開發相關的高成本和技術問題
  • 市場機會
    • 將生物標記物與人工智慧和機器學習結合
    • 人們對開發先進的非侵入性生物標記越來越感興趣
  • 市場挑戰
    • 關於使用生物標記的倫理和法律問題

波特的五力：駕馭生物標記市場的策略工具

波特的五力架構是了解生物標記市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生物標記市場的外部影響

外部宏觀環境因素在塑造生物標記市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解生物標記市場的競爭狀況

生物標記物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生物標記市場供應商的績效評估

FPNV定位矩陣是評估生物標記市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製生物標記市場的成功之路

生物標記市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 更多使用生物標記來早期檢測和診斷慢性病
      • 政府和監管機構對生物標記研究的支持
      • 擴大生物標記在個人化醫療的應用
    • 抑制因素
      • 與生物標記開發相關的高成本和技術問題
    • 機會
      • 將生物標記物與人工智慧和機器學習結合
      • 人們對開發先進的非侵入性生物標記越來越感興趣
    • 任務
      • 關於使用生物標記的倫理和法律問題
  • 市場區隔分析
    • 產品和服務：擴大採用先進且易於使用的生物標記軟體來處理複雜的生物資料。
    • 應用：生物標記在藥物開發中確定產品功效和安全性的應用正在擴大。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生物標記市場：依產品/服務分類

  • 消耗品
  • 服務
  • 軟體

第7章生物標記市場：依類型

  • 功效生物標記
    • 動態標記
    • 預測生物標記
    • 預測生物標記
    • 替代生物標記
  • 安全生物標記
  • 檢驗生物標記

第8章生物標記市場：依疾病分類

  • 癌症
  • 心血管疾病
  • 免疫疾病
  • 感染疾病
  • 神經系統疾病

第9章生物標記市場：依應用分類

  • 臨床診斷
  • 臨床調查
  • 藥物發現與開發
  • 個人化醫療

第10章美洲生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Owlstone Medical 的創新計畫獲得比爾及梅琳達蓋茲基金會的資助
    • 開創性研究合作加強轉移性大腸直腸癌的治療
    • FDA 啟動試驗計畫來監管腫瘤藥物的伴同性診斷測試
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Abcam PLC
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix
  • Biocrates Life Sciences AG
  • Biofourmis Inc.
  • Biognosys AG
  • BioStarks
  • Charles River Laboratories, Inc.
  • Elo Health, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KgaA
  • Nightingale Health Plc
  • Owkin Inc.
  • Owlstone Medical Limited
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • Proteomedix AG
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Thermo Fisher Scientific, Inc.
  • VivoSense, Inc
Product Code: MRR-A339DAEFACD9

The Biomarkers Market was valued at USD 52.50 billion in 2023, expected to reach USD 59.69 billion in 2024, and is projected to grow at a CAGR of 14.19%, to USD 132.98 billion by 2030.

Biomarkers, or biological markers, are distinctive biological signatures found in bodily fluids or tissues that indicate normal or abnormal conditions, stage of a disease, or the effects of treatment. They are critical for diagnostics, clinical trials, personalized medicine, and drug development, enhancing understanding of disease mechanisms and treatment efficacy. Biomarkers are used in areas like oncology, cardiology, neurology, and infectious diseases. Market growth is driven by increased prevalence of chronic diseases, technological advancements in biomarker research, and a surge in demand for precision medicine. Innovations in genomic biomarkers, especially through advances in AI and data analytics, present vast opportunities, particularly in tailoring individualized treatment plans and predicting disease progression. Emerging fields like liquid biopsy and multi-omic biomarkers are notable for their potential in earlier and more precise disease detection. Nonetheless, challenges include high costs of validation, regulatory complexities, and ethical issues related to genetic data privacy. Moreover, the heterogeneity of diseases and the lack of standardization in biomarker validation impede expansive market growth. Continued innovation is possible through research into non-invasive biomarkers and AI-enhanced analytical tools. Integration of digital health data and real-world evidence can lead to more predictive diagnostics. Companies can gain competitive advantage by investing in collaborations across industries, ensuring robust interdisciplinary approaches to biomarker discovery. Encouraging open data sharing and standardization protocols can ameliorate some existing barriers. As the biomarker market evolves, an agile approach to regulatory changes and technological advancements will be key for sustained growth. Emphasizing partnerships with healthcare providers and patients will further innovate biomarker applications, leading to significant advancements in health outcomes and market penetration in personalized healthcare solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 52.50 billion
Estimated Year [2024] USD 59.69 billion
Forecast Year [2030] USD 132.98 billion
CAGR (%) 14.19%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biomarkers Market

The Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of biomarkers in early detection and diagnosis of chronic disease
    • Governments and regulatory support for biomarker research
    • Growing applications of biomarkers in personalized medicine
  • Market Restraints
    • High cost and technical issues associated with developing biomarkers
  • Market Opportunities
    • Integration of biomarkers with artificial intelligence and machine learning
    • Growing interest in developing advanced noninvasive biomarkers
  • Market Challenges
    • Ethical and legal concerns regarding the use of biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biomarkers Market

A detailed market share analysis in the Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biomarkers Market

A strategic analysis of the Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BioStarks, Charles River Laboratories, Inc., Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Siemens Healthineers AG, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product & Service, market is studied across Consumables, Services, and Software.
  • Based on Type, market is studied across Efficacy Biomarkers, Safety Biomarkers, and Validation Biomarkers. The Efficacy Biomarkers is further studied across Pharmacodynamic Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, and Surrogate Biomarkers.
  • Based on Disease, market is studied across Cancer, Cardiovascular Diseases, Immunological Diseases, Infectious Diseases, and Neurological Diseases.
  • Based on Application, market is studied across Clinical Diagnostics, Clinical Research, Drug Discovery & Development, and Personalized Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of biomarkers in early detection and diagnosis of chronic disease
      • 5.1.1.2. Governments and regulatory support for biomarker research
      • 5.1.1.3. Growing applications of biomarkers in personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and technical issues associated with developing biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of biomarkers with artificial intelligence and machine learning
      • 5.1.3.2. Growing interest in developing advanced noninvasive biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and legal concerns regarding the use of biomarkers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product & Service: Growing adoption of sophisticated and user-friendly biomarker software to handle the complexity of biological data
    • 5.2.2. Application: Growing applications of biomarkers in drug development to determine the efficacy and safety of the product
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biomarkers Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Software

7. Biomarkers Market, by Type

  • 7.1. Introduction
  • 7.2. Efficacy Biomarkers
    • 7.2.1. Pharmacodynamic Biomarkers
    • 7.2.2. Predictive Biomarkers
    • 7.2.3. Prognostic Biomarkers
    • 7.2.4. Surrogate Biomarkers
  • 7.3. Safety Biomarkers
  • 7.4. Validation Biomarkers

8. Biomarkers Market, by Disease

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Immunological Diseases
  • 8.5. Infectious Diseases
  • 8.6. Neurological Diseases

9. Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics
  • 9.3. Clinical Research
  • 9.4. Drug Discovery & Development
  • 9.5. Personalized Medicine

10. Americas Biomarkers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biomarkers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biomarkers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Owlstone Medical's Novel Initiatives Receive the Bill & Melinda Gates Foundation Funding
    • 13.3.2. Pioneering Research Collaboration to Enhance Treatment for Metastatic Colorectal Cancer
    • 13.3.3. FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abcam PLC
  • 3. APIS Assay Technologies Limited
  • 4. Augurex Life Sciences Corp
  • 5. Bio-Rad Laboratories, Inc.
  • 6. BioAgilytix
  • 7. Biocrates Life Sciences AG
  • 8. Biofourmis Inc.
  • 9. Biognosys AG
  • 10. BioStarks
  • 11. Charles River Laboratories, Inc.
  • 12. Elo Health, Inc.
  • 13. F. Hoffmann-La Roche, Ltd.
  • 14. Merck KgaA
  • 15. Nightingale Health Plc
  • 16. Owkin Inc.
  • 17. Owlstone Medical Limited
  • 18. PerkinElmer, Inc.
  • 19. Personalis, Inc.
  • 20. Proteomedix AG
  • 21. QIAGEN GmbH
  • 22. Siemens Healthineers AG
  • 23. Sino Biological Inc.
  • 24. Thermo Fisher Scientific, Inc.
  • 25. VivoSense, Inc

LIST OF FIGURES

  • FIGURE 1. BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOMARKERS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOMARKERS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACODYNAMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOMARKERS MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOMARKERS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOMARKERS MARKET SIZE, BY SURROGATE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOMARKERS MARKET SIZE, BY SAFETY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOMARKERS MARKET SIZE, BY VALIDATION BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOMARKERS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOMARKERS MARKET SIZE, BY IMMUNOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023